A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

摘要: Object The presence of angiogenesis is a hallmark glioblastoma (GBM). Vascular endothelial growth factor (VEGF), which drives angiogenesis, provides an additional target for conventional therapy. authors conducted prospective clinical trial to test the effectiveness bevacizumab, inhibitor VEGF, in newly diagnosed GBM. Methods From 2006 through 2010, 51 eligible patients with GBM were treated involved-field radiation therapy and concomitant temozolomide (75 mg/m2 daily 42 days) along bevacizumab (10 mg/kg every 2 weeks), starting 29 days after surgery. This was followed by 6 cycles adjuvant (150 on Days 1–7 28-day cycle) administered at 10 8 22 each cycle. Results 6- 12-month progression-free survival (PFS) rates 85.1% 51%, respectively. 12- 24-month overall (OS) 42.5%, Grade III/IV toxicities noted pa...